Previous 10 | Next 10 |
home / stock / brrgf / brrgf news
OSLO, Norway , June 14, 2019 /PRNewswire/ -- Two posters to be presented at the 2019 annual congress of the European Hematology Association on 14th June Phase II trial evaluating bemcentinib in combination with low-intensity chemotherapy in elderly acute myeloid leukaemia (AML) patie...
BERGEN, Norway , May 15, 2019 /PRNewswire/ -- Two peer reviewed abstracts on Phase II clinical data with bemcentinib accepted for presentation at ASCO 2019 Non-Small-Cell Lung Cancer (NSCLC) trial of bemcentinib in combination with pembrolizumab, data to be presented includes safety...
Phase II, Simon two-stage trial evaluating bemcentinib and KEYTRUDA in previously treated NSCLC post chemotherapy (Cohort A, NCT03184571) First stage previously met efficacy endpoint Second stage enrolled a further 24 patients for a total of 48; efficacy and biomarker data updat...
BergenBio ( OTCPK:BRRGF ): Q1 GAAP EPS of -NOK0.81. More news on: BerGenBio ASA, Earnings news and commentary, Healthcare stocks news, , Read more ...
- Advanced leukaemia (AML/MDS): Phase II trial fully recruited and combination trial with low-intensity chemotherapy meets efficacy endpoint in hard to treat relapsed / refractory (R/R) leukaemia - Advanced lung cancer (NSCLC): Additional cohort added in trial of bemcentinib in combinat...
- Phase II data in AML combining bemcentinib with low-dose chemotherapy and NSCLC combining with KEYTRUDA - Accepted for presentation at ASCO in June 2019 OSLO, Norway , April 23, 2019 /PRNewswire/ -- BerGenBio ASA (OSE: BGBIO) a clinical-stage biopharmaceuti...
BERGEN, Norway , April 9, 2019 /PRNewswire/ -- BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company focused on developing a pipeline of first-in-class drug candidates targeting AXL kinase to treat aggressive diseases including immune-evasive and therapy resistant cancers,...
BerGenBio ASA ( OTCPK:BRRGF ) has dosed first patient in an additional cohort ("Cohort B") of an ongoing Phase II open-label study of selective AXL inhibitor bemcentinib in combination with Merck's (NYSE: MRK ) anti-PD-1 therapy KEYTRUDA (pembrolizumab) in previously treated pati...
- First patient dosed in new cohort of Phase II trial evaluating selective AXL inhibitor bemcentinib in combination with KEYTRUDA in patients with advanced NSCLC whose disease is progressing on anti-PD(L)1 therapy - New cohort added under existing collaborative agreement with Merck asses...
Extensive data in pre-clinical models of non-small cell lung cancer (NSCLC) and pancreatic cancer demonstrating AXL's role in reversing tumour-mediated immunosuppression and therapy resistance presented at AACR Selective AXL inhibitor, bemcentinib, shown to reverse AXL's effects, thus act...
News, Short Squeeze, Breakout and More Instantly...
Brent Resources Group Ltd Company Name:
BRRGF Stock Symbol:
OTCMKTS Market:
Bergenbio Presents Encouraging Updated Preliminary Data From Phase Ii Study In Relapsed Aml Patients At Eha Virtual Meeting Encouraging updated preliminary survival data more than double standard of care reported in relapsed AML patients PR Newswire BERGEN, Norway ...
BerGenBio Presents Updated Clinical Data From Two Phase II Studies Of Bemcentinib in AML and MDS Patients At Ash 2020 BERGEN, Norway , Dec. 6, 2020 /PRNewswire/ -- BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL...
BerGenBio Presents Phase II Bemcentinib Combination Study in NSCLC at Annual SITC Meeting PR Newswire BERGEN, Norway, Nov. 11, 2020 BERGEN, Norway , Nov. 11, 2020 /PRNewswire/ -- BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing...